Neuroscience
Parkinson's Disease
100%
Parkinsonism
36%
L-DOPA
35%
Dyskinesia
32%
Virus Vector
26%
Ketamine
26%
Dopamine Transporter
23%
Decision-Making
21%
Anesthetics
20%
Ioflupane (123I)
19%
Tetrodotoxin
19%
Sodium Channel
19%
Dopaminergic
19%
Electrical Brain Stimulation
17%
Single-Photon Emission Computed Tomography
16%
Subthalamic Nucleus
15%
Green Fluorescent Protein
14%
Basal Ganglia
14%
In Vitro
14%
Familial Parkinson's Disease
13%
Vasculotropin B
13%
Herpes
13%
Pigment Epithelium Derived Factor
13%
Vascular Endothelial Growth Factor
13%
Potassium Channel
13%
Neurite
13%
Putamen
12%
Saxitoxin
11%
Attention Deficit Hyperactivity Disorder
11%
Behavior (Neuroscience)
11%
Kv1.1
11%
Neurite Outgrowth
10%
Neuroprotective Agent
9%
In Vivo
9%
Striatum
9%
Stereotypic Movement Disorder
9%
Treatment of Parkinson's Disease
9%
Brain-Derived Neurotrophic Factor
7%
Neurodegenerative Disorder
7%
Reinforcement Learning
7%
Brain Imaging
7%
Innervation
7%
Skeletal Muscle
7%
Hippocampus
6%
Parkin
6%
Reporter Gene
6%
Gene Expression
6%
Voltage Clamp
6%
Working Memory
6%
Hydrogen Peroxide
6%
Keyphrases
Levodopa-induced Dyskinesia
30%
Parkinson's Disease
29%
L-DOPA
22%
123I-IMP
19%
Parkinson's Disease Model
17%
Ketamine
16%
Ketamine Treatment
14%
Intravenous Ketamine
14%
Dyskinetic
14%
Dopamine Transporter Imaging
13%
Pigment Epithelium-derived Factor
13%
Vascular Endothelial Growth Factor B
13%
Opioid Receptors
13%
Rodent Models
13%
Neuronal Culture
13%
Receptor Antagonism
13%
Parkinsonian Syndromes
12%
Abnormal Involuntary Movements
10%
Dopaminergic Neurons
9%
Vascular Endothelial Growth Factor
9%
High Cell Density Culture
8%
Herpes Simplex
8%
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
8%
Parkinsonism
7%
Broadband gamma
7%
Cross-frequency Coupling
7%
Parkinson Patients
6%
Neurotrophic Factors
6%
Performance Assessment
6%
Parkin mutation
6%
Kv1.1
6%
Neuropathic Pain
6%
Sodium Channel
6%
Post-error Slowing
6%
Subthalamic nucleus
6%
Differential Effects
6%
Viral Vectors
6%
Muscle Cells
6%
Disease Association
6%
Rat Model of Parkinson's Disease
6%
Penetration Analysis
6%
Morphological Changes
6%
Neurological Conditions
6%
Heart Rate Variability
6%
In-home
6%
Preclinical in Vivo Models
6%
Tetrodotoxin
6%
Action Selection
6%
Cervical Dystonia
6%
Bupropion Sustained Release
6%
Pharmacology, Toxicology and Pharmaceutical Science
Levodopa-Induced Dyskinesia
42%
Parkinson's Disease
39%
Ketamine
26%
DOPA
20%
Neuropathic Pain
13%
Pigment Epithelium Derived Factor
13%
Sodium Channel
13%
Tetrodotoxin
13%
Opiate Receptor
13%
Ioflupane (123I)
13%
Saxitoxin
9%
Dyskinesia
9%
Antiparkinson Agent
8%
Disease
7%
Repurposing
7%
Frailty
6%
Microcarrier
6%
Vasculotropin B
6%
Receptor
6%
Cervical Dystonia
6%
Electroacupuncture
6%
Tizanidine
6%
Dopamine 1 Receptor
6%
Dopamine Receptor D2
6%
Dextro Aspartic Acid
6%
Methyldienolone
6%
Dopamine Transporter
6%
Neurotrophic Factor
6%
Reserpine
6%
Sustained Release
6%
Brain Infarction
6%
Kappa Opiate Receptor
6%
Vasculotropin
6%
Bupropion
6%
Visual Pigment
6%
Parkinsonism
6%
